ESPE Abstracts

This study aimed to evaluate final adult height after recombinant growth hormone (GH) treatment in girls with Turner syndrome (TS) and elucidate the contributing factors to growth response. (Seventy-four patients with Turner syndrome who were treated with GH and reached adult height and 18 patients without treatment were enrolled in this study. To determine final height gain, we assessed the difference between the final height standard deviation score (SDS) and height SDS at the initiation of treatment. In addition, the difference between the final height and predicted adult height at the initiation of treatment was assessed. GH therapy was initiated at a mean age of 8.91±3.71 years in TS patients. The mean duration of GH therapy was 6.42±3.03 years. The mean height at the initiation of treatment was 116.54±16.66 cm, and height SDS was −3.73±1.48. Patients who underwent GH treatment reached an adult height of 152.08±4.67 cm, and final height SDS was −1.96±1.50. The difference between final adult height and predicted adult height was 6.20±1.20 cm. Final height SDS was found to have a significantly positive correlation with height SDS at the initiation of treatment (P<0.001) and mid-parental height SDS (P<0.001). In addition, the final height was influenced by confounding variables including the duration of GH therapy, chronological age at the initiation of treatment and karyotype. Height SDS gain was found to have a significantly positive correlation with height SDS at the initiation of treatment (P<0.001), chronological age at the initiation of treatment (P<0.007) and the duration of GH therapy (P<0.015). Our findings demonstrate that GH therapy seems effective in improving final height SDS and height SDS gain in TS patients, and that early intervention of GH administration in patients with TS seems to be necessary for final height gain.